Overview
News
Technologies
Salaries
Products
People
Growth
Offices
Financials

Funding and backers

Team
51-200
employees, estimated range
Hiring now
4
open roles
Backers
2
Atinum Investment, LB Investment
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Apr 13 Board appointment Orum Therapeutics Appoints Dr. Maria Koehler and Geoff Meyerson to Board of Directors · morningstar.com Jan 4 New executive Orum Therapeutics Appoints Chad May as Chief Scientific Officer to Drive Degrader-Antibody Conjugate Innovation and Programs · businesswire.com Oct 14, 2025 New executive Orum Therapeutics Appoints Dr. Dorin Toader as Head of Platform Technology to Advance Orum's Degrader-Antibody Conjugate Payload Platforms and Expand… · streetinsider.com
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
immunitoAIVenture round $6.1M · 10 mo ago • Founded 2020 • 11-50 employees • 1 role
immunitoAI is an AI-driven biotechnology company accelerating antibody discovery and the development of antibody-based therapies through…
Magnet Biomedicine is advancing monovalent molecular glue inhibitors (MGIs) and innovative protein degraders to engage disease drivers.
PROTEINA4 roles
PROTEINA is a South Korean biotechnology company that uses its own SPID single-molecule protein-protein interaction detection technology to…
NeomorphSeries B $100M · 6 mo ago • Founded 2020
We engineer neomorphic protein surfaces to unlock targeted protein degradation.
Hone BioVenture round · 23 mo ago • Founded 2024 • 1-10 employees
Hone Bio develops NanoPilot, a dual-targeting technology that enables cell-specific LNP delivery whilst actively blocking off-target…
BiotheryxVenture round $92.1M · 5 yr ago • 201-500 employees
Degrading proteins.Saving lives.. Biotheryx is advancing a portfolio of first-in-class protein degraders, with an initial focus on…

How Orum Therapeutics hires

Truth index
B 75/100
Ghost roles
0%
Stale roles
100%
Reposted roles
0%

Orum Therapeutics scores B on the Alion truth index (A is best, E worst), measured over 3 open roles re-checked against its own hiring board: 0% look like ghost listings, 100% have gone stale and 0% are the same role posted again. It measures how much of what this employer publishes turns into a real, finite search - not the employer as a workplace. How the index is computed

Overview

Pioneering the development of cell-specific, targeted protein degraders with the precision of antibody targeting.

News

News CHOSUNBIZ 2 months ago
Orum Therapeutics wins FDA nod to start phase 1 trial for AML drug
Orum Therapeutics wins FDA nod to start phase 1 trial for AML drug IND greenlight paves way for first-in-human test of dac therapy orm-1153 in relapse
Read more
Report
News Pulse 2.0 9 months ago
Orum Therapeutics Names Chad May As Chief Scientific Officer
Orum Therapeutics, a biotechnology company developing degrader-antibody conjugates (DACs), has appointed Chad May, Ph.D., as Chief Scientific Officer, bringing more than two decades of oncology and immunology R&D experience spanning antibody-drug conjugat
Read more
Report
News YahooFinance 11 months ago
Orum Therapeutics Announces Presentation of Preclinical Data for ORM-1153 at the 2025 American Society of Hematology (ASH) Annual Meeting
BOSTON & DAEJEON, South Korea, November 03, 2025--Orum Therapeutics Announces Presentation of Preclinical Data for ORM-1153 at the 2025 American Society of Hematology (ASH) Annual Meeting
Read more
Report
News WRAL.com 20 years ago
Raleigh, NC Breaking News, Weather, Traffic - WRAL NBC affiliate
Get the latest Raleigh area news, weather forecasts, I-40 traffic, ACC and high school sports, strange news and blogs for Central and Eastern North Carolina, including Raleigh, Durham, Cary, Chapel Hill, Fayetteville, Rocky Mount and Wilson.
Read more
Report

Tech stack

Technologies named in job postings at Orum Therapeutics over the last 12 months, by layer, with the share of postings for each.
Technologies in use
1
Postings analysed
1
Stack modernity
64/100
Cloud & platforms
GCP
Sign in to see how your skills match this stack Sign In

Growth

Hiring Momentum
23/100
Hiring freeze
Open positions
4
0 opened / 0 closed in 30 days
Median time-to-fill
63 days
faster than 21% of the market
ATS activity
Every ~4 hours
Today
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Finance
50% ▼
Management
50% ▼

Offices

Where the company hires and what each office is for
Cities
2
Hiring now
2
Countries
2
Busiest office
Lexington
Loading the map
Headquarters Builds here Office with open vacancies Tap a pin for the office
Lexington United States
2 open roles 1 posted in 90 days 100% engineering 50-200 est. staff
hires for Science & Research
seen since Apr 2026 job postings
Daejeon South Korea
2 open roles 1 posted in 90 days 10-50 est. staff
hires for Finance, Legal
seen since Jul 2026 job postings